- Details
- Description
-
Packaging Size42c/Box
-
Strength50mg
-
CompositonSurufatinib
-
TreatmentpNETs and epNETS
-
Formcapsule
-
Brand苏泰达 (SULANDA)
-
Quantity Unit50mg*42c/Box
-
ManufacturerHUTCHMED.,China
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factor receptors (VEGFR) and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Its unique dual mechanism of action may be very suitable for possible combinations with other immunotherapies, where there may be synergistic anti-tumor effects.
- Surufatinib sold as brand name 苏泰达® (SULANDA) in china.
In China,Surufatinib being approved in China in June 2021 and December 2020 for pNETs and epNETS.
